Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

pembrolizumab 2Nivolumab 2Ipilimumab 2sodium thiosulfate 1relacorilant 1lenvatinib 1cabozantinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1E-7386 1Cytoreduction Surgical Procedures 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adrenocortical Carcinoma × pembrolizumab × Clear all
NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT05036434 2026-01-23

ACCOMPLISH

National Cancer Center, Korea

Phase 2 Active not recruiting
30 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡